Ghaziabad Online

Non-Muscle Invasive Bladder Cancer Pipeline, Emerging therapies and Drugs by DelveInsight

 Breaking News
  • No posts were found

Non-Muscle Invasive Bladder Cancer Pipeline, Emerging therapies and Drugs by DelveInsight

February 03
11:23 2021
Non-Muscle Invasive Bladder Cancer Pipeline, Emerging therapies and Drugs by DelveInsight

DelveInsight has launched a new report onNon-Muscle Invasive Bladder Cancer Pipeline

 

Non-muscle invasive bladder cancer (NMIBC) formerly known as superficial bladder cancer, is a common, heterogeneous disease associated with high rates of recurrence that often requires lifelong surveillance. The cancer is found in the tissue that lines the inner surface of the bladder wherein the bladder muscle is not involved.

 

Request for free sample copy- https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight

 

Non-Muscle Invasive Bladder Cancer Pipeline analysis across different stages of development (Phase I, II, and III), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key competitors, launch date along with product development activities

 

Non-Muscle Invasive Bladder Cancer Pipeline

The high-grade NMIBC pipeline possesses potential drugs in mid and late stage developments to be launched in the near future. The major key players include Viventia Bio/Sesen Bio (Vicinium), FKD Therapies Oy/Ferring Pharmaceuticals (Adstiladrin), CG Oncology (CG0070), ImmunityBio/Altor Biosciences (N-803 (ALT-803)), Theralase (TLD-1433), Merck (Keytruda) and others that hold the potential to create a significant positive shift in NMIBC in the market size.

 

Marketed drugs included in the report

  • Keytruda (pembrolizumab): Merck
  • Valstar (valrubicin): Endo Pharmaceuticals

 

Emerging drugs included in the report

  • Vicinium: Sesen Bio
  • Adstiladrin (nadofaragene firadenovec/Syn3): FKD Therapies Oy/ Ferring Pharmaceuticals
  • Tecentriq (atezolizumab): Hoffmann-La Roche
  • Sasanlimab (PF-06801591) + BCG: Pfizer
  • Apaziquone: Spectrum Pharmaceuticals
  • Opdivo (nivolumab): Bristol-Myers Squibb
  • Imfinzi (durvalumab): AstraZeneca
  • VesiGel (UGN-102/mitomycin gel): UroGen Pharma
  • And many others

 

Non-Muscle Invasive Bladder Cancer Emerging Therapy

Keytruda is developed by Merck and marketed in the United States which is a humanized monoclonal antibody that binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including anti-tumor immune response. The drug is also in trial for Europe and Japan.

 

Non-Muscle Invasive Bladder Cancer Emerging Therapy Assessment

CG Oncology is developing CG0070 which has completed phase II clinical developmental trial and is planning to initiate a phase III trial for the patients with NMIBC. CG0070, a selectively replicative oncolytic immunotherapy based on a modified adenovirus type 5 backbone that contains a cancer-selective promoter and a GM-CSF transgene, destroys bladder tumor cells through their defective Rb pathway. CG0070 was designed to work in two complementary ways. First, it replicates inside the tumor’s cells with dysfunctional Rb pathways, causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, which can stimulate a systemic antitumor immune response that involves the body’s white blood cells.

 

Non-Muscle Invasive Bladder Cancer Companies

  • Merck
  • Endo Pharmaceuticals
  • Sesen Bio
  • Ferring Pharmaceuticals
  • And many others

 

Non-Muscle Invasive Bladder Cancer Symptoms

Some people may have symptoms that suggest they have bladder cancer. Others may feel nothing at all. Some symptoms should never be ignored. Some of the common symptoms are:

  • Hematuria (blood in the urine) – the most common symptom, often without pain
  • Frequent and urgent urination
  • Pain when urine passes
  • Pain in lower abdomen
  • Back pain

 

Non-Muscle Invasive Bladder Cancer Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Non-muscle invasive bladder cancer R&D. The therapies under development are focused on novel approaches to treat/improve Non-muscle invasive bladder cancer.
  • In August 2018, Sesen Bio announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Vicinium for the treatment of BCG-unresponsive high-grade non-muscle invasive bladder cancer (NMIBC).
  • The FDA granted Instiladrin, Breakthrough Therapy designation and its Biologics License Application (BLA) has been accepted for filing and granted Priority Review.
  • In September 2019, Anchiano Therapeutics reported that it had entered into an exclusive worldwide collaboration and option to license agreement with ADT Pharmaceuticals to develop novel small-molecule inhibitors of RAS and PDE10/β-catenin. This collaboration reflects Anchiano’s ongoing strategy to grow a pipeline beyond its pivotal-stage asset, inodiftagene vixteplasmid, with programs that have the potential to address significant clinical needs, while leveraging Anchiano’s expertise in small-molecule oncology development. 
  • LiPax Platform is a proprietary proliposomal intracavitary paclitaxel drug delivery platform designed to enhance the therapeutic index of proven cancer drugs, which results in more effective treatments for intracavitary cancers. LIPAC’s lead drug candidate, LiPax, is a locally delivered formulation of the well-established chemotherapy drug, paclitaxel. It is in Phase 1/2a clinical trial for non-muscle invasive bladder cancer (NMIBC) and has demonstrated impressive initial clinical activity while being very well tolerated. LiPax is also in preclinical development for upper tract urothelial carcinoma (UTUC), ovarian cancer, intraperitoneal carcinoma, and mesothelioma/malignant pleural effusion

 

Request for free sample copy- https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight

 

Table of content

  • Introduction
  • Executive Summary
  • Non-muscle invasive bladder cancer: Overview
  • Pipeline Therapeutics
  • Therapeutic Assessment
  • Non-muscle invasive bladder cancer – DelveInsight’s Analytical Perspective
  • In-depth Commercial Assessment
  • Non-muscle invasive bladder cancer Collaboration Deals
  • Late Stage Products
  • Vicinium : Sesen Bio
  • APL-1202: Asieris Pharmaceuticals
  • Mid Stage Products
  • UGN-102: UroGen Pharma
  • Balversa: Janssen Pharmaceuticals
  • Early Stage Products
  • UGN-201: UroGen Pharma
  • E7766: H3 Biomedicine
  • Pre-clinical and Discovery Stage Products
  • ATX 101: APIM Therapeutics
  • Inactive Products
  • Non Muscle Invasive Bladder Cancer Key Companies
  • Non Muscle Invasive Bladder Cancer Key Products
  • Non Muscle Invasive Bladder Cancer- Unmet Needs
  • Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
  • Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
  • Non Muscle Invasive Bladder Cancer Analyst Views
  • Non Muscle Invasive Bladder Cancer Key Companies
  • Appendix

 

Related Reports

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/ghaziabadonline/public_html/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share

Recent Posts

Temporary Labor Market Revenue To Hit $673.43 Billion By 2025 – Vendor Landscape, End-Use Outlook And Strategic Initiatives | Million Insights

Read Full Article

Categories